ORX-750

Centessa Pharmaceuticals appointed Stephen Kanes as Chief Medical Officer, leveraging his 30+ years of experience in neuroscience and drug development.

Nxera Pharma has enrolled the first patient in a Phase 3 clinical trial in South Korea to evaluate daridorexant for treating insomnia.

Centessa Pharmaceuticals has commenced a Phase 2 clinical trial of ORX750 for narcolepsy type 1 (NT1), narcolepsy type 2 (NT2), and idiopathic hypersomnia.

Bright Minds Biosciences is collaborating with Firefly Neuroscience to analyze EEG data from the Phase 2 BREAKTHROUGH study of BMB-101.

Centessa Pharmaceuticals' ORX750, an orexin receptor 2 (OX2R) agonist, demonstrated significant improvements in wakefulness in sleep-deprived healthy volunteers.